18889881171
Kalkine 0
countryflagUS

Applied Therapeutics Inc

Healthcare US APLT

0.4163USD
0.04(10.16%)

Last update at 2025-05-22T16:55:00Z

Day Range

0.380.42
LowHigh

52 Week Range

1.1810.62
LowHigh

Fundamentals

  • Previous Close 0.38
  • Market Cap144.28M
  • Volume1023808
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-92.28400M
  • Revenue TTM-0.21200M
  • Revenue Per Share TTM-0.002
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -82.50800M -105.58400M -93.96100M -45.51300M -16.52100M
Minority interest - - - - 0.00000M
Net income -81.68900M -104.61400M -93.02200M -45.39700M -16.52100M
Selling general administrative 27.32M 43.05M 32.68M 13.23M 2.05M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.44M 0.41M 0.38M 0.02M -
Ebit -82.95000M -106.03300M -94.84600M -45.60500M -10.29400M
Ebitda -82.88400M -105.61800M -94.46600M -45.58200M -13.29700M
Depreciation and amortization 0.07M 0.41M 0.38M 0.02M -3.00300M
Non operating income net other - - -0.05400M - -
Operating income -82.95000M -105.61800M -94.46600M -45.58200M -13.51800M
Other operating expenses 82.95M 105.62M 94.47M 45.58M 13.52M
Interest expense -0.44200M 0.56M 0.56M 0.09M 0.00000M
Tax provision - - - - -
Interest income 0.69M - - 0.09M 2.78M
Net interest income 0.69M 0.56M 0.56M 0.09M -1.64200M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.81900M -0.97000M -0.93900M -0.11600M 4.87M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 82.95M 105.62M 94.47M 45.58M 13.52M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.44M 0.03M 0.51M 0.07M -1.36100M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -82.50800M -105.58400M -93.96100M -45.51300M -16.52100M
Net income applicable to common shares - -105.58400M -93.96100M -45.51300M -16.52100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 54.83M 38.36M 89.89M 104.51M 48.39M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.20M 6.73M 7.57M 5.76M 7.30M
Total liab 71.98M 34.30M 27.35M 22.57M 15.78M
Total stockholder equity -17.14600M 4.06M 62.54M 81.94M 32.61M
Deferred long term liab - - - - -
Other current liab 68.34M 28.41M 0.99M 0.55M 0.26M
Common stock 0.00800M 0.00500M 0.00300M 0.00200M 0.00100M
Capital stock 0.00800M 0.00500M 0.00300M 0.00200M 0.00100M
Retained earnings -468.58600M -348.82300M -266.31500M -160.73100M -66.77000M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - 0.20M 1.91M 0.20M
Cash 49.90M 16.66M 53.89M 57.47M 18.85M
Cash and equivalents - - - - -
Total current liabilities 71.18M 33.42M 26.46M 21.23M 14.10M
Current deferred revenue 0.67M - 15.57M 19.64M 4.69M
Net debt -48.67200M -15.76600M -52.55500M -55.72800M -16.81100M
Short term debt 0.43M 0.48M 0.44M 0.41M 0.36M
Short long term debt 0.31M 0.62M 0.79M 1.07M -
Short long term debt total 1.23M 0.89M 1.33M 1.74M 2.04M
Other stockholder equity 451.43M 352.83M 328.96M 242.78M 50.99M
Property plant equipment - - 1.30M 1.71M 2.04M
Total current assets 54.39M 37.31M 88.39M 102.59M 46.16M
Long term investments - - - - 0.20M
Net tangible assets - - 62.54M 81.94M 32.61M
Short term investments 0.00000M 13.92M 26.93M 39.36M 20.00M
Net receivables 0.28M 0.28M 0.53M 0.51M -
Long term debt - 0.46M - - -
Inventory - -0.27500M -0.52500M -0.50500M -
Accounts payable 1.74M 4.53M 9.46M 0.64M 8.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.05M -0.10700M -0.11200M -0.00200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00200M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -160.73100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.20M -26.93500M - 0.20M
Deferred long term asset charges - - - - -
Non current assets total 0.45M 1.05M 1.50M 1.91M 2.23M
Capital lease obligations 0.47M 0.89M 1.33M 1.74M 2.04M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 13.17M 12.43M -19.46900M -20.00600M -20.00600M
Change to liabilities - 8.82M -8.04400M 5.75M 2.30M
Total cashflows from investing activities - 12.43M -19.46900M -20.00600M -20.00600M
Net borrowings - -4.71800M -2.14800M -2.14800M 6.00M
Total cash from financing activities 27.69M 74.72M 136.29M 56.41M 26.65M
Change to operating activities - -5.15300M 13.20M -2.52100M -0.23800M
Net income -82.50800M -105.58400M -93.96100M -45.51300M -16.52100M
Change in cash -37.23100M -3.57800M 38.62M 0.10M 15.47M
Begin period cash flow 53.89M 57.47M 18.85M 18.75M 3.28M
End period cash flow 16.66M 53.89M 57.47M 18.85M 18.75M
Total cash from operating activities -78.09300M -90.72800M -78.20900M -36.30700M -11.18200M
Issuance of capital stock 27.81M 74.42M 134.10M 58.69M 21.16M
Depreciation 0.44M 0.41M 0.38M 0.02M 0.02M
Other cashflows from investing activities - - - -20.00600M 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - 1.12M -2.49800M 21.21M
Other cashflows from financing activities 3.15M 0.30M 4.34M 3.20M 26.65M
Change to netincome - 10.77M 10.22M 5.95M 3.27M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - 1.56M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 38.62M - -
Change in working capital -8.84400M 3.67M 5.15M 3.23M 2.06M
Stock based compensation 9.16M 11.18M 8.03M 6.17M 0.27M
Other non cash items 3.65M -0.40400M -0.36000M -0.21800M 3.00M
Free cash flow -78.09300M -90.72800M -78.20900M -36.30700M -11.18200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APLT
Applied Therapeutics Inc		 0.04 10.16% 0.42 - - 54.68 25.28 62.37 -9.711
NVO
Novo Nordisk A/S		 -0.155 0.23% 68.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.95 1.40% 68.95 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.41 1.01% 430.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -10.3 1.70% 594.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics Inc

545 Fifth Avenue, New York, NY, United States, 10017

Key Executives

Name Title Year Born
Dr. Shoshana Shendelman Ph.D. Chair of the Board of Directors, Founder, Pres, CEO & Sec. 1979
Dr. Riccardo Perfetti M.D., Ph.D. Chief Medical Officer 1960
Mr. Chids Mahadevan Sr. VP of Fin. & Interim Principal Financial Officer 1970
Mr. Steven Ortega Chief Accounting Officer 1986
Mr. Adam Hansard Chief Commercial Officer 1976
Dr. Shoshana Shendelman Ph.D. Chair of the Board of Directors, Founder, President, CEO & Secretary 1979
Mr. Les D. Funtleyder CFO, Principal Financial Officer & Independent Director 1971
Dr. Riccardo Perfetti M.D., Ph.D. Chief Medical Officer 1961
Mr. Adam Hansard Chief Commercial Officer 1977
Mr. Constantine Chinoporos COO & Chief Business Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.